法學期刊
論著名稱: 提高回覆 C 肝新藥交互作用效率之方案
編著譯者: 廖玲嬋
出版日期: 2018.05
刊登出處: 台灣/醫療品質雜誌第 12 卷 第 3 期 /36-41 頁
頁  數: 6 點閱次數: 197
下載點數: 24 點 銷售明細: 權利金查詢 變更售價
授 權 者: 財團法人醫院評鑑暨醫療品質策進會 授權者指定不分配權利金給作者)
關 鍵 詞: C 型肝炎藥物交互作用直接抗病毒藥物
中文摘要: 目前 C 型肝炎治療仍無有效疫苗可預防,但近年來有突破性發展,從單一傳統干擾素(interferon)到長效型干擾素(peginterferon alfa,PegIFN)併用雷巴威林(ribavirin,RBV),又進展為直接作用抗病毒藥品(direct-acting antiviral agents, DAAs),讓評估慢性 C 型肝炎治療成效指標之持續病毒學反應 (sustained virologic response, SVR)比率達到 90% 以上。但因直接作用抗病毒藥品價格昂貴,又容易有交互作用,故如何提高藥師回覆交互作用的效率,是必須努力的方向。我們採用 APP 軟體與廠商諮詢專線取代原本的 Micromedex 查詢,改善後發現能有效縮短查詢時間,病人滿意度從 3.2±0.7 分,上升至 4.6±0.4 分(P 值=0.04)。藥師滿意度也從 3.1±0.4 分,上升至 4.8±0.2 分(P 值=0.02)。
英文關鍵詞: hepatitis C virusdrug interactiondirect-acting antiviral
英文摘要: A vaccine against hepatitis C virus (HCV) has yet to be developed. However, the development of treatments for chronic HCV infection has accelerated over the past few years; rapid progress has been made from traditionally prescribed single interferon medication to combined pegylated interferon and ribavirin, and finally to direct-acting antivirals (DAAs). Patients treated with DAAs have exhibited a sustained virologic response rate of 90%; however, oral DAA regimens are expensive and frequently interact with other drugs. Thus, pharmacists require an effective method to avoid dispensing drugs that interfere with one another. In this study, we proposed the use of a smartphone APP and drug counseling hotline for seeking information on drug interactions to replace the Micromedex and effectively shorten search times. We found that patient satisfaction increased from 3.2 ± 0.7 to 4.6 ± 0.4 points (P = 0.04). In addition, pharmacist satisfaction increased from 3.1 ± 0.4 to 4.8 ± 0.2 points (P = 0.02).
目  次: 闡述對象
研究方法
改善步驟
結果與討論
結論
參考文獻
相關法條:
    相關判解:
      相關函釋:
        相關論著:
          返回功能列